Clinical trials: Oral Phase
Healthy
A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants
Part 1 aims to investigate the relative bioavailability of a new formulation and to assess potential food effects following oral administration of SYT-510.
- Trial name
- NCT06670950
- Testing
- SYT-510
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Synendos Therapeutics AG
Relapsed Advanced Lymphomas
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
- Trial name
- ADITI-1 (NCT06755450)
- Testing
- AUR112
- Where
- 19 sites in India
- Volunteers
- 40 people
- Sponsor
- Aurigene Discovery Technologies Limited
Ulcerative Colitis
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well…
- Trial name
- NCT06254950
- Testing
- TAK-279
- Where
- 141 sites in United States, Australia and 20 more
- Volunteers
- 213 people
- Sponsor
- Takeda
Multiple Myeloma
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy.
- Trial name
- NCT00445068
- Testing
- LBH589
- Where
- 29 sites in United States, Germany
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Participants
Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants
The purpose of this study is to identify drug levels of gastro-retentive (GR) formulations which prolong retaining time in the stomach of deucravacitinib (BMS-986165) in Healthy Participants.
- Trial name
- NCT06566768
- Testing
- Deucravacitinib
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Parkinson Disease
Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients
This will be a double-blind, randomised, placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced…
- Trial name
- AMBLED (NCT03162874)
- Testing
- PXT002331 - dose 1, PXT002331 - dose 2
- Where
- 45 sites in Austria, France and 4 more
- Volunteers
- 157 people
- Sponsor
- Prexton Therapeutics
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Contraception
Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm
The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.
- Trial name
- ATI-CL13 (NCT01236768)
- Testing
- AG200-15, Levora
- Where
- 21 sites in United States
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Agile Therapeutics
Elderly Study Participants, Adult Study Participants
A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants
The purpose of the study is to evaluate the plasma pharmacokinetic of padsevonil in adult and elderly study participants.
- Trial name
- NCT04013191
- Testing
- Padsevonil
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Safety, Pharmacokinetics, Pharmacodynamics, Food Effect
Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of AZD7986 in healthy volunteers
- Trial name
- NCT02303574
- Testing
- AZD7986, oral solution, 1 to 50 mg/mL
- Where
- United Kingdom
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-Muscle Invasive Bladder Cancer (NMIBC)
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is administered alone and concurrently with BCG.
- Trial name
- NMIBC (NCT03672240)
- Testing
- APL-1202
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Asieris Pharmaceutical Technologies Co., Ltd.
Obesity
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06568731
- Testing
- Danuglipron
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Advanced Solid Tumors
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
This study has two parts: Dose Escalation and Dose Expansion. The primary objective of the study, in the Dose Escalation Part is to determine the recommended phase 2 dose (RP2D) of Debio 0123 when administered in combination with…
- Trial name
- NCT03968653
- Testing
- Debio 0123, Carboplatin
- Where
- 8 sites in Netherlands, Spain
- Volunteers
- 76 people
- Sponsor
- Debiopharm International SA
Hepatic Impairment
A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment
The purpose is to evaluate the pharmacokinetics (PK) of a single oral dose of 600 milligram (mg) pimodivir in adult participants with impaired hepatic function compared to adult participants with normal hepatic function.
- Trial name
- NCT03816631
- Testing
- Pimodivir
- Where
- 2 sites in Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Parkinson's Disease
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
- Trial name
- NCT04165837
- Testing
- FB-101
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Ejaculation
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
Assessment of efficacy and safety UK-390,957.
- Trial name
- NCT00219583
- Testing
- UK-390,957
- Where
- 49 sites in Australia, Austria and 12 more
- Volunteers
- 460 people
- Sponsor
- Pfizer
Breast Neoplasms
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
The purpose of this study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women with estrogen receptor positive (ER+), human…
- Trial name
- NCT02374099
- Testing
- CC-486, Fulvestrant
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 97 people
- Sponsor
- Celgene
Normal Healthy
Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects
The current study is the first clinical trial proposed with PF-05221304. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single and repeated doses of PF-05221304 to…
- Trial name
- NCT02871037
- Testing
- PF-05221304
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pharmacokinetics
Food Effects on Bioavailability of MDMA in Healthy Volunteers
The goal of this clinical trial is to learn if food impacts absorption of MDMA in participants who are either fed or fasted. The main question it aims to answer is: What is the effect of eating food on the safety of taking oral…
- Trial name
- MPKF (NCT05147402)
- Testing
- midomafetamine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.